Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2017

View Archived Issues

Blockade of G-CSF receptor found to improve arthritic pain in mice

NIH grant supports UIC evaluation of TAT-PTEN9c to improve survival post heart attack

Transcription elongation factors as novel therapeutic targets in glioblastoma

Axsome initiates phase II/III trial of AXS-05 for Alzheimer's disease agitation

Novartis has 5-year data for Cosentyx in plaque psoriasis

Rv3723/LucA as a promising new target for Mycobacterium tuberculosis infection

Wave begins PRECISION-HD program for WVE-120101 and WVE-120102 in Huntington's disease

Proellex to remain on partial clinical hold

CymaBay reports promising interim phase II data on seladelpar in primary biliary cholangitis

FDA grants priority review to voretigene neparvovec BLA

REDX-05194 ameliorates diabetic nephropathy in mice by reducing inflammasome activation

FDA approves Nerlynx as extended adjuvant therapy for early stage HER2-positive breast cancer

NICE final guidance recommends Humira, Enbrel and Stelara for plaque psoriasis in children

Julius-Maximilians-Universitaet Wuerzburg divulges polypeptides for thrombotic disorders

Paratek reports promising topline phase III data for omadacycline in ABSSSI

Flatley Discovery Lab identifies CFTR channel correctors

Chugai Pharmaceutical presents antibodies for treating muscle wasting

Norgine completes Merus acquisition

Ligand grants Amgen commercial rights to use Captisol technology in formulation of AMG-330

New phase II trial investigates CPP-1X in patients at high risk of gastric cancer

CStone cleared to begin clinical trials of CS-1001 in China

New murine model of celiac disease developed

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...